PriceTargets.com logo

Anika Therapeutics - ANIK Stock Price Target and Predictions

  • Consensus Rating: Hold
  • Consensus Price Target: $28.50
  • Forecasted Upside: 1.71%
  • Number of Analysts: 2
  • Breakdown:
  • 0 Sell Ratings
  • 2 Hold Ratings
  • 0 Buy Ratings
  • 0 Strong Buy Ratings
$28.02 As of 03/24/2023 01:00 AM ET
▼ -0.03 (-0.11%)

This chart shows the closing price for ANIK by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Anika Therapeutics Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for ANIK and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for ANIK

Analyst Price Target is $28.50
▲ +1.71% Upside Potential
This price target is based on 2 analysts offering 12 month price targets for Anika Therapeutics in the last 3 months. The average price target is $28.50, with a high forecast of $31.00 and a low forecast of $26.00. The average price target represents a 1.71% upside from the last price of $28.02.

This chart shows the closing price for ANIK for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Hold

The current consensus among 2 polled investment analysts is to hold stock in Anika Therapeutics. This Hold consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 0 buy ratings
  • 2 hold ratings
  • 0 sell ratings
Ratings as of
10/2/2021
  • 0 strong buy ratings
  • 0 buy ratings
  • 3 hold ratings
  • 0 sell ratings
Ratings as of
12/31/2021
  • 0 strong buy ratings
  • 0 buy ratings
  • 3 hold ratings
  • 0 sell ratings
Ratings as of
3/31/2022
  • 0 strong buy ratings
  • 0 buy ratings
  • 3 hold ratings
  • 0 sell ratings
Ratings as of
6/29/2022
  • 0 strong buy ratings
  • 0 buy ratings
  • 2 hold ratings
  • 0 sell ratings
Ratings as of
9/27/2022
  • 0 strong buy ratings
  • 0 buy ratings
  • 2 hold ratings
  • 0 sell ratings
Ratings as of
12/26/2022
  • 0 strong buy ratings
  • 0 buy ratings
  • 2 hold ratings
  • 0 sell ratings
Ratings as of
2/24/2023
  • 0 strong buy ratings
  • 0 buy ratings
  • 2 hold ratings
  • 0 sell ratings
Ratings as of
3/26/2023

Latest Recommendations

  • 0 strong buy ratings
  • 0 buy ratings
  • 2 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
3/7/2023Barrington ResearchDowngradeOutperform ➝ Market PerformLow
11/9/2022Barrington ResearchUpgradeMarket Perform ➝ Outperform$31.00Low
10/14/2022StephensReiterated RatingEqual Weight$26.00Low
10/13/2022StephensInitiated CoverageEqual WeightLow
3/9/2022Barrington ResearchDowngradeOutperform ➝ Market PerformHigh
3/9/2022StephensDowngradeOverweight ➝ Equal Weight$35.00High
11/15/2021StephensInitiated CoverageOverweight$55.00Medium
11/5/2021Barrington ResearchBoost TargetOutperform$44.00 ➝ $48.00Medium
7/16/2021UBS GroupInitiated CoverageNeutral$46.00Low
12/16/2020Barrington ResearchUpgradeMarket Perform ➝ Outperform$43.00High
5/8/2020Barrington ResearchDowngradeOutperform ➝ Market PerformHigh
2/21/2020Barrington ResearchReiterated RatingBuy$60.00Low
1/21/2020SidotiUpgradeNeutral ➝ Buy$61.00Low
1/10/2020First AnalysisUpgradeOutperform ➝ Strong-Buy$65.00Low
11/5/2019BWS FinancialInitiated CoverageSell$29.00High
10/25/2019SidotiSet TargetHold$50.00N/A
9/24/2019Barrington ResearchReiterated RatingOutperform$49.00 ➝ $58.00Medium
9/23/2019First AnalysisDowngradeStrong-Buy ➝ Outperform$54.00Low
7/25/2019Barrington ResearchReiterated RatingBuy$45.00 ➝ $49.00High
7/25/2019First AnalysisUpgradeNeutral ➝ Strong-Buy$37.00 ➝ $54.00High
3/5/2019SidotiSet TargetHold$35.00Low
2/28/2019Singular ResearchReiterated RatingBuyMedium
2/22/2019Barrington ResearchLower TargetOutperform$44.00High
2/22/2019SidotiDowngradeBuy ➝ Neutral$56.00 ➝ $41.00High
2/22/2019First AnalysisDowngradeOutperform ➝ Neutral$41.00 ➝ $37.00High
7/27/2018Barrington ResearchUpgradeMarket Perform ➝ Outperform$48.00Medium
6/20/2018Barrington ResearchDowngradeOutperform ➝ Market PerformHigh
6/20/2018First AnalysisDowngradeOverweight ➝ Equal Weight$45.00 ➝ $34.00High
5/4/2018Barrington ResearchUpgradeMarket Perform ➝ Outperform$39.00High
(Data available from 3/26/2018 forward)

News Sentiment Rating

0.37 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 1 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
8/28/2022
  • 0 very positive mentions
  • 3 positive mentions
  • 2 negative mentions
  • 0 very negative mentions
Mentions as of
9/27/2022
  • 4 very positive mentions
  • 8 positive mentions
  • 1 negative mentions
  • 1 very negative mentions
Mentions as of
10/27/2022
  • 2 very positive mentions
  • 8 positive mentions
  • 2 negative mentions
  • 0 very negative mentions
Mentions as of
11/26/2022
  • 2 very positive mentions
  • 11 positive mentions
  • 2 negative mentions
  • 1 very negative mentions
Mentions as of
12/26/2022
  • 3 very positive mentions
  • 19 positive mentions
  • 1 negative mentions
  • 1 very negative mentions
Mentions as of
1/25/2023
  • 8 very positive mentions
  • 8 positive mentions
  • 1 negative mentions
  • 2 very negative mentions
Mentions as of
2/24/2023
  • 5 very positive mentions
  • 15 positive mentions
  • 0 negative mentions
  • 1 very negative mentions
Mentions as of
3/26/2023

Current Sentiment

  • 5 very positive mentions
  • 15 positive mentions
  • 0 negative mentions
  • 1 very negative mentions

Recent Stories by Sentiment

Very Negative

Negative

  • No negative mentions tracked during this time.

Positive

Very Positive

Anika Therapeutics logo
Anika Therapeutics, Inc. is an orthopedic and regenerative medicines company, which develops, manufactures and commercializes therapeutic products for pain management, tissue regeneration, and wound healing. Its products are based on hyaluronic acid, a natural chemical occurring, biocompatible polymer found throughout the body. It offers therapeutic products which include orthobiologics, dermal, ophthalmic, surgical, ophthalmic and veterinary. The company was founded in 1992 and is headquartered in Bedford, MA.
Read More

Today's Range

Now: $28.02
Low: $27.51
High: $28.14

50 Day Range

MA: $29.86
Low: $25.91
High: $32.10

52 Week Range

Now: $28.02
Low: $19.95
High: $32.51

Volume

64,670 shs

Average Volume

109,679 shs

Market Capitalization

$409.93 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.86

Frequently Asked Questions

What sell-side analysts currently cover shares of Anika Therapeutics?

The following Wall Street research analysts have issued reports on Anika Therapeutics in the last year: Barrington Research, Stephens, and StockNews.com.
View the latest analyst ratings for ANIK.

What is the current price target for Anika Therapeutics?

2 Wall Street analysts have set twelve-month price targets for Anika Therapeutics in the last year. Their average twelve-month price target is $28.50, suggesting a possible upside of 1.7%. Barrington Research has the highest price target set, predicting ANIK will reach $31.00 in the next twelve months. Stephens has the lowest price target set, forecasting a price of $26.00 for Anika Therapeutics in the next year.
View the latest price targets for ANIK.

What is the current consensus analyst rating for Anika Therapeutics?

Anika Therapeutics currently has 2 hold ratings from Wall Street analysts. The stock has a consensus analyst rating of "Hold." A "hold" rating indicates that analysts believe investors should keep any existing positions they have in ANIK, but not buy more shares or sell existing shares.
View the latest ratings for ANIK.

What other companies compete with Anika Therapeutics?

Other companies that are similar to Anika Therapeutics include OraSure Technologies, Utah Medical Products, Cerus, Atrion and MiMedx Group. Learn More about companies similar to Anika Therapeutics.

How do I contact Anika Therapeutics' investor relations team?

Anika Therapeutics' physical mailing address is 32 WIGGINS AVENUE, BEDFORD MA, 01730. The biotechnology company's listed phone number is (781) 457-9000 and its investor relations email address is [email protected] The official website for Anika Therapeutics is www.anikatherapeutics.com. Learn More about contacing Anika Therapeutics investor relations.